Incomplete septal fibrosis

  • 文章类型: Journal Article
    窦口血管综合征的特征是不包括肝硬化的特定组织学变化,有或没有门静脉高压症。患者通常无症状,直到门静脉高压并发症发展。
    一名69岁女性,有JAK2阳性原发性血小板增多症(ET)病史,由于肝酶升高,被转诊至内科咨询。患者既往无肝病史。七个月前,她患有缺血性卒中,开始接受阿托伐他汀治疗.停药后,肝酶恢复正常,推测与阿托伐他汀相关的药物性肝病(DILI).在后续访问中,检测到缺铁性贫血,并进行了内镜研究.它显示胃静脉曲张积极出血,成功用氰基丙烯酸酯处理。两个月后,该患者因静脉曲张破裂出血而入院,并进行了门静脉高压症的补充研究。
    尽管对门窦血管疾病(PSVD)的发病机制知之甚少,肝脏内的血管变化与几种易感疾病有关,如高凝状态。ET患者,尤其是那些有JAK2突变的人,已知非肝硬化静脉血栓形成的风险增加。关于PSVD,这种关联尚不清楚,但人们认为PSVD和骨髓增殖性肿瘤有一个共同点:一种以高凝状态为特征的状态,炎症,内皮功能障碍和,在某些情况下,门静脉高压症。
    没有肝硬化的门脉高压是一种罕见的疾病,提出诊断挑战和对患者预后的重大影响。
    结论:当门脉高压征象出现正常或轻度升高的肝酶和正常的肝硬度测量时,应增加对PSVD的怀疑。在这种情况下应进行肝活检。虽然PSVD的发病机制尚不清楚,它是基于肝脏内血管变化的发展,可能有几种诱发疾病,如凝血障碍。
    UNASSIGNED: Porto-sinusoidal vascular syndrome is characterised by specific histological changes that do not include cirrhosis, with or without portal hypertension. Patients are usually asymptomatic until development of portal hypertension complications.
    UNASSIGNED: A 69-year-old female with history of JAK2 positive essential thrombocythemia (ET) was referred to internal medicine consultation due to elevated liver enzymes. The patient had no previous history of liver disease. Seven months earlier, she had an ischaemic stroke and started treatment with atorvastatin. After discontinuing medication, liver enzymes returned to normal and atorvastatin-related drug-induced liver disease (DILI) was presumed.During a follow-up visit, iron deficiency anaemia was detected and an endoscopic study was performed. It revealed a gastric varix actively bleeding, which was successfully treated with cyanoacrylate.Two months later, the patient was admitted due to a new episode of variceal bleeding, and a portal hypertension complementary study was made.
    UNASSIGNED: Although the pathogenesis of porto-sinusoidal vascular disease (PSVD) remains poorly understood, vascular changes within the liver have been associated with several predisposing conditions, such as hypercoagulable states. Patients with ET, especially those with JAK2 mutation, are known to be at increased risk of non-cirrhotic vein thrombosis. Concerning PSVD, the association is not clear but it is believed that both PSVD and myeloproliferative neoplasms share a common denominator: a state characterised by hypercoagulability, inflammation, endothelial dysfunction and, in some cases, portal hypertension.
    UNASSIGNED: Portal hypertension without cirrhosis is a rare condition, presenting diagnostic challenges and significant impact on the patient\'s prognosis.
    CONCLUSIONS: The suspicion of PSVD should be raised when signs of portal hypertension are present with normal or mildly elevated liver enzymes and normal liver stiffness measurement. A liver biopsy should be performed in this situation.Although the pathogenesis of PSVD is not clearly understood, it is based on the development of vascular changes within the liver and there might be several predisposing conditions such as coagulation disorders.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    众所周知,门脉高压可以在没有肝硬化的情况下发生,据报道,在免疫疾病患者中,感染和血栓形成倾向。然而,在没有门静脉高压症的患者中也观察到主要影响肝窦和(周围)门静脉系统的类似组织学异常。因此,最近引入了术语门窦血管疾病(PSVD)来描述一组肝脏血管疾病,其特征是病变包括门静脉和窦状,无论是否存在门静脉高压症。肝活检是PSVD诊断的基础。具体的组织学发现包括结节性再生增生,闭塞性门静脉病/门静脉狭窄和不完全性间隔纤维化/肝硬化。由于其他条件,包括酒精相关和非酒精性脂肪肝疾病,或者病毒性肝炎,或者在PSVD患者中可能发生门静脉血栓形成,应仔细评估它们对肝损伤的相对贡献。除了组织学和临床诊断标准,影像学检查和非侵入性检查,如肝脏和脾脏硬度测量,可能有助于诊断检查。PSVD作为一种新型临床实体的引入将促进对该术语所涵盖的潜在分子病理机制的合作研究和调查。
    It is well established that portal hypertension can occur in the absence of cirrhosis, as reported in patients with immune disorders, infections and thrombophilia. However, similar histological abnormalities primarily affecting the hepatic sinusoidal and (peri)portal vasculature have also been observed in patients without portal hypertension. Thus, the term porto-sinusoidal vascular disorder (PSVD) has recently been introduced to describe a group of vascular diseases of the liver featuring lesions encompassing the portal venules and sinusoids, irrespective of the presence/absence of portal hypertension. Liver biopsy is fundamental for PSVD diagnosis. Specific histology findings include nodular regenerative hyperplasia, obliterative portal venopathy/portal vein stenosis and incomplete septal fibrosis/cirrhosis. Since other conditions including alcohol-related and non-alcoholic fatty liver disease, or viral hepatitis, or the presence of portal vein thrombosis may occur in patients with PSVD, their relative contribution to liver damage should be carefully assessed. In addition to histology and clinical diagnostic criteria, imaging and non-invasive tests such as liver and spleen stiffness measurements could aid in the diagnostic workup. The introduction of PSVD as a novel clinical entity will facilitate collaborative studies and investigations into the underlying molecular pathomechanisms encompassed by this term.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号